Gossamer Bio, Inc. has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to implement a 1-for-80 reverse stock split of its common stock. The split became effective at 11:59 p.m. Eastern Time on September 10, 2026.
Under the terms of the amendment, every 80 shares of common stock issued and outstanding immediately prior to the effective time were automatically reclassified and combined into one share of common stock. The company noted that no fractional shares will be issued; instead, holders of record entitled to a fraction of a share will receive a fraction necessary to round up to the nearest whole share.
Shares of the company’s common stock are expected to begin trading on a split-adjusted basis on the Nasdaq Global Select Market at the market open on September 11, 2026. The trading symbol “GOSS” will remain unchanged, and a new CUSIP number of 38341P 201 has been assigned.
In connection with the split, the number of authorized shares of common stock was reduced from 4,000,000,000 to 50,000,000. The total number of authorized shares of capital stock was correspondingly reduced from 4,070,000,000 to 120,000,000.
The company stated that the reverse stock split is intended to help it regain compliance with the Nasdaq Global Select Market’s minimum bid price requirement. To regain compliance, the closing bid price of the common stock must be at least $1.00 per share for a minimum of 10 consecutive business days before the compliance date of October 5, 2026.
The split also proportionately adjusted the conversion rates of outstanding convertible notes, including the 5.00% Convertible Senior Notes due 2027 and the 7.50% Convertible Senior Secured First Lien Notes due 2030. Additionally, the number of shares issuable upon exercise of outstanding warrants and prefunded warrants, as well as the number of shares subject to outstanding equity awards, were adjusted to reflect the new ratio.
